Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Protection of cardiac cell-to-cell coupling attenuate myocardial remodeling and proarrhythmia induced by hypertension

T. Egan Benova, B. Szeiffova Bacova, C. Viczenczova, E. Diez, M. Barancik, N. Tribulova

. 2016 ; 65 (Suppl. 1) : S29-S42. (Advances in cardiovascular research)

Language English Country Czech Republic

Document type Journal Article, Review

Gap junction connexin channels are important determinants of myocardial conduction and synchronization that is crucial for coordinated heart function. One of the main risk factors for cardiovascular events that results in heart attack, congestive heart failure, stroke as well as sudden arrhythmic death is hypertension. Mislocalization and/or dysfunction of specific connexin-43 channels due to hypertension-induced myocardial remodeling have been implicated in the occurrence of life-threatening arrhythmias and heart failure in both, humans as well as experimental animals. Recent studies suggest that down-regulation of myocardial connexin-43, its abnormal distribution and/or phosphorylation might be implicated in this process. On the other hand, treatment of hypertensive animals with cardioprotective drugs (e.g. statins) or supplementation with non-pharmacological compounds, such as melatonin, omega-3 fatty acids and red palm oil protects from lethal arrhythmias. The antiarrhythmic effects are attributed to the attenuation of myocardial connexin-43 abnormalities associated with preservation of myocardial architecture and improvement of cardiac conduction. Findings uncover novel mechanisms of cardioprotective (antihypertensive and antiarrhythmic) effects of compounds that are used in clinical settings. Well-designed trials are needed to explore the antiarrhythmic potential of these compounds in patients suffering from hypertension.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17021010
003      
CZ-PrNML
005      
20181120141139.0
007      
ta
008      
170623s2016 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.933391 $2 doi
035    __
$a (PubMed)27643938
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Egan Benová, Tamara, $d 1985- $7 xx0229479 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovakia
245    10
$a Protection of cardiac cell-to-cell coupling attenuate myocardial remodeling and proarrhythmia induced by hypertension / $c T. Egan Benova, B. Szeiffova Bacova, C. Viczenczova, E. Diez, M. Barancik, N. Tribulova
520    9_
$a Gap junction connexin channels are important determinants of myocardial conduction and synchronization that is crucial for coordinated heart function. One of the main risk factors for cardiovascular events that results in heart attack, congestive heart failure, stroke as well as sudden arrhythmic death is hypertension. Mislocalization and/or dysfunction of specific connexin-43 channels due to hypertension-induced myocardial remodeling have been implicated in the occurrence of life-threatening arrhythmias and heart failure in both, humans as well as experimental animals. Recent studies suggest that down-regulation of myocardial connexin-43, its abnormal distribution and/or phosphorylation might be implicated in this process. On the other hand, treatment of hypertensive animals with cardioprotective drugs (e.g. statins) or supplementation with non-pharmacological compounds, such as melatonin, omega-3 fatty acids and red palm oil protects from lethal arrhythmias. The antiarrhythmic effects are attributed to the attenuation of myocardial connexin-43 abnormalities associated with preservation of myocardial architecture and improvement of cardiac conduction. Findings uncover novel mechanisms of cardioprotective (antihypertensive and antiarrhythmic) effects of compounds that are used in clinical settings. Well-designed trials are needed to explore the antiarrhythmic potential of these compounds in patients suffering from hypertension.
650    _2
$a zvířata $7 D000818
650    _2
$a antiarytmika $x farmakologie $x terapeutické užití $7 D000889
650    _2
$a antioxidancia $x farmakologie $x terapeutické užití $7 D000975
650    _2
$a konexin 43 $x metabolismus $7 D018031
650    _2
$a omega-3 mastné kyseliny $x farmakologie $x terapeutické užití $7 D015525
650    _2
$a mezerový spoj $x ultrastruktura $7 D017629
650    _2
$a srdce $x účinky léků $7 D006321
650    _2
$a lidé $7 D006801
650    _2
$a hypertenze $x farmakoterapie $x metabolismus $x patologie $7 D006973
650    _2
$a melatonin $x farmakologie $x terapeutické užití $7 D008550
650    _2
$a myokard $x ultrastruktura $7 D009206
650    _2
$a oleje rostlin $x farmakologie $x terapeutické užití $7 D010938
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Szeiffová Bačová, B $7 xx0307206 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovakia
700    1_
$a Viczenczová, C. $7 _AN092152 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovakia
700    1_
$a Diez, E. $u Institute of Physiology, Faculty of Medicine, National University of Cuyo, Argentina
700    1_
$a Barančík, Miroslav $7 xx0089695 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovakia
700    1_
$a Tribulová, Narcisa, $d 1946- $7 xx0104473 $u Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovakia
773    0_
$w MED00003824 $t Physiological research. Advances in cardiovascular research $x 1802-9973 $g Roč. 65, Suppl. 1 (2016), s. S29-S42
773    0_
$t Advances in cardiovascular research $g (2016), s. S29-S42 $w MED00196543
856    41
$u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20170623 $b ABA008
991    __
$a 20181120141233 $b ABA008
999    __
$a ok $b bmc $g 1236306 $s 981883
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 65 $c Suppl. 1 $d S29-S42 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $o Advances in cardiovascular research $x MED00003824
BMC    ##
$a 2016 $d S29-S42 $m Advances in cardiovascular research $x MED00196543
LZP    __
$b NLK118 $a Pubmed-20170623

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...